Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Aurora Cannabis Inc. resulting from allegations that Aurora might have issued misleading information to the investing public. If you purchased Aurora securities, andor would like to discuss your legal rights and options please visit ACB Shareholder Investigation or ...

Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Aurora Cannabis Inc. ("Aurora" or the "Company") (NYSE: ACB) resulting from allegations that Aurora might have issued misleading information to the investing public.

If you purchased Aurora securities, and/or would like to discuss your legal rights and options please visit ACB Shareholder Investigation or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com .

On September 8, 2020, Aurora issued a press release "announc[ing] an update on its business operations along with certain unaudited preliminary fiscal fourth-quarter 2020 results." Among other things, Aurora announced that the Company expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. The Company also announced that "previously announced fixed asset impairment charges [were] now expected to be up to $90 million, due to production facility rationalization, and a charge of approximately $140 million in the carrying value of certain inventory, predominantly trim, in order to align inventory on hand with near term expectations for demand."

On this news, Aurora's stock price fell $0.99 per share, or 11.63% to close at $7.52 per share on September 8, 2020.

If you purchased Aurora securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/auroracannabisinc-acb-shareholder-class-action-stock-fraud-lawsuit-322/apply/ or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com .

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2020 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com

News Provided by Business Wire via QuoteMedia

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Analytical testing will accelerate Numinus' Research and Development capabilities and generate revenue through third-party clients

Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a leader in psychedelics-focused mental healthcare, has today announced novel, proprietary methods for psychedelic mushroom compound screening. The testing, which was developed and validated in-house, will be available as part of its service offerings for third-party clients and used for evidence-based conversations with the regulators.

Keep reading... Show less

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Cronos Group Inc. - CRON1111

Pomerantz LLP is investigating claims on behalf of investors of Cronos Group Inc. ("Cronos" or the "Company") (NASDAQ: CRON). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Cronos and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Keep reading... Show less
cannabis plant layered with German flag graphic

Cannabis Weekly Round-Up: Germany Moves Ahead on Path to Adult Use

Three political parties have formed a coalition in Germany, leading to a new government, and it has promised cannabis reform in the European nation.

Meanwhile, a popular cannabis retailer confirmed consumers will now find its products available for delivery on the Uber Eats mobile application in Ontario.

Keep reading to find out more cannabis highlights from the past five days.

Keep reading... Show less
HEMPSANA Announces Q3 2021 Financial Results

HEMPSANA Announces Q3 2021 Financial Results

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.

Hempsana Holdings Ltd. (the " Company " or " Hempsana ") today announced third quarter ("Q3") financial results for the three- and nine-month period ended September 30, 2021.

Keep reading... Show less
Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

Numinus Receives Conditional Approval to Graduate to the Toronto Stock Exchange

 Numinus Wellness Inc. ("Numinus" or the "Company") (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that it has received conditional approval from the Toronto Stock Exchange ("TSX") to graduate its listing from the TSX Venture Exchange (the "TSXV") to the TSX.

"This is an important milestone for Numinus, as we take key steps to heighten our corporate profile and reach a broader range of investors," said Payton Nyquvest , Founder and CEO of Numinus. "Today's announcement is reflective of many exciting developments occurring at Numinus. We're actively growing our clinic network across North America , expanding our lab capabilities, and strategically investing in clinical research to drive long-term value creation for our investors."

Keep reading... Show less
MediPharm Labs Completes Medical Cannabis Export to Barbados

MediPharm Labs Completes Medical Cannabis Export to Barbados

  • Patient based delivery of medical cannabis executed with approval from both Barbados and Canadian Health Authorities.
  • This marks the fourth new country entered by MediPharm Labs in 2021, following initial shipments to Germany, Brazil and Peru.

MediPharm Labs Corp . (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) ("MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a medical cannabis export to Barbados in conjunction with strategic partner Avicanna (TSX: AVCN).

"Our GMP platform make us the go-to partner for companies looking to access global medical cannabis programs," said Bryan Howcroft, CEO, MediPharm Labs. "As countries around the world continue to adopt medical cannabis programs, MediPharm Labs is best positioned to serve these markets as the only North American producer with a Drug Establishment License (GMP) for the extraction of natural cannabinoids."

Keep reading... Show less

Top News

Related News